

17 October 2025

ASX RELEASE

AMPLIA THERAPEUTICS TO SIGNIFICANTLY EXPAND U.S. PRESENCE THROUGH EXPANSION OF CLINICAL AND INVESTOR FACING ACTIVITIES

IN SUPPORT OF ITS ONGOING PHASE 2A CLINICAL TRIAL IN PANCREATIC CANCER IN U.S. CENTRES, THE COMPANY HAS LAUNCHED A CAPITAL MARKETS CAMPAIGN TO INCREASE INVESTOR AWARENESS, INCLUDING INITIATING AN UPLIST TO THE OTCQB MARKET

Melbourne, Australia: Amplia Therapeutics Limited (ASX: ATX) (“Amplia” or the “Company”) announces it has initiated a program to expand its presence in the United States with the end goal of expanding investor awareness and engagement. The Company is currently conducting its Phase 1b/2a clinical trial in pancreatic cancers in centres both in Australia and the U.S. Concurrently, Amplia CEO Dr. Chris Burns is actively educating investors on Amplia’s FAK inhibitor program for pancreatic cancer as part of an expanded capital markets campaign. The campaign includes activities with several financial institutions and a filing to uplist from the Pink Sheet to the OTCQB exchange, which is intended to measurably increase access to the Company’s stock for U.S. investors.

Dr. Burns stated, “As we continue to conduct our Phase 1b/2a clinical trial of narmafotinib, including in the United States, we believe it is important that we reach investors there to help support the program and development of the compound. We believe narmafotinib represents a unique opportunity in the FAK inhibitor class, potentially providing improved balance between efficacy, safety and tolerability beyond what is currently available in the U.S. market and within the class as a whole. The OTCQB market is a unique opportunity to introduce ourselves to the U.S. market and significantly expand our U.S. investor base. We look forward to launching our capital markets campaign and to telling the Amplia story there.”

This ASX announcement was approved and authorised for release by the Board of Amplia Therapeutics.

Investor Contact:

Dr Chris Burns
Chief Executive Officer
chris@ampliatx.com

U.S. Contact:

Robert Giordano
rjgiordano@ggrouplifesciences.com

Media Contact:

HACK Director, Haley Chartres
haley@hck.digital
+61 423 139 163

U.S. Media:

media@ampliatx.com

ABN 16 165 160 841

+61 (0) 3 9123 1140 | info@ampliatx.com
Level 5, 90 William Street, Melbourne VIC 3000 Australia

www.ampliatx.com

About Amplia Therapeutics Limited

Amplia Therapeutics Limited is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. FAK is an increasingly important target in the field of cancer and Amplia has a particular development focus in fibrotic cancers such as pancreatic and ovarian cancer. FAK also plays a significant role in a number of chronic diseases, such as idiopathic pulmonary fibrosis (IPF). For more information visit www.ampliatx.com and follow Amplia on [X](#) (@ampliatx) and [LinkedIn](#).

About Narmafotinib

Narmafotinib (AMP945) is the company's best-in-class inhibitor of the protein FAK, a protein over-expressed in pancreatic cancer and a drug target gaining increasing attention for its role in solid tumours. The drug, which is a highly potent and selective inhibitor of FAK, has shown promising data in a range of preclinical cancer studies. Narmafotinib is currently undergoing a clinical trial (the [ACCENT](#) trial) where it is dosed in combination with the chemotherapies gemcitabine and Abraxane in first-line patients with advanced pancreatic cancer. The trial has already achieved its desired outcome in achieving a response rate of 33%, superior to chemotherapy alone and an interim PFS of 7.6 months has been reported. A second trial – AMPLICITY – has recently opened and is being run under an IND at sites in Australia and the US, investigating the combination of narmafotinib with the chemotherapy FOLFIRINOX in advanced pancreatic cancer patients.